ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 219 • 2015 ACR/ARHP Annual Meeting

    Targeted Deep Resequencing Identifies MRP4/ABCC4 as a Gout Risk Locus in the New Zealand Mä�ori and Pacific Island Populations

    Tony R. Merriman1, James Boocock2, Callum Tanner2, Murray Cadzow2, Amanda Phipps-Green2, Lisa K. Stamp3, Nicola Dalbeth4, Jennie Harre Hindmarsh5, David B. Mount6, Hyon Choi7 and Eli A. Stahl8, 1Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 2University of Otago, Dunedin, New Zealand, 3Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 4Department of Medicine, University of Auckland, Auckland, New Zealand, 5Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, 6Renal Division, Brigham and Women's Hospital, Boston, MA, 7Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 8Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Genetic variants in uric acid transporters that control serum urate levels in Europeans have been identified by genome-wide association studies. However there is no…
  • Abstract Number: 220 • 2015 ACR/ARHP Annual Meeting

    A Genome-Wide Association Study Reveals Association of the Transferrin Receptor Locus with Gout

    Tony R. Merriman1, Murray Cadzow2, Callum Tanner2, Matthew A. Brown3, Katie Cremin4, Matthijs Janssen5, Tim Jansen6, Leo A. Joosten7, Timothy Radstake8, Philip L. Riches9, Anne-Kathrin Tausche10, Frederic Lioté11, Alex So12,13, Andre M. van Rij2, Gregory T. Jones14, Lisa K. Stamp15, Nicola Dalbeth16 and Cushla McKinney2, 1Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 2University of Otago, Dunedin, New Zealand, 3The University of Queensland Diamantina Institute, Brisbane, Australia, 4Diamantina Institute, University of Queensland, Brisbane, Australia, 5Rheumatology Dept, Ziekenhuis Rijnstate, Arnhem, Netherlands, 6P O Box 581, Haarlem, Netherlands, 7Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 8Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 9Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom, 10Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, 11Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, 12Service De Rhumatologie, CHUV, Lausanne, Switzerland, 13Department of Rheumatology, CHUV, Lausanne, Switzerland, 14Surgery, University of Otago, Dunedin, New Zealand, 15Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 16Department of Medicine, University of Auckland, Auckland, New Zealand

    Background/Purpose: Acute gouty arthritis results from an innate immune response to monosodium urate (MSU) crystals deposited in the joints and soft tissues of hyperuricaemic individuals.…
  • Abstract Number: 221 • 2015 ACR/ARHP Annual Meeting

    Clinical and Genetic Characteristics of Diuretic-Associated Gout: A Case-Control Study

    Sirisha Mitnala1, Amanda Phipps-Green2, Christopher Franklin1, Anne Horne3, Lisa K. Stamp4, Tony R. Merriman5 and Nicola Dalbeth1,3, 1University of Auckland, Auckland, New Zealand, 2University of Otago, Dunedin, New Zealand, 3Department of Medicine, University of Auckland, Auckland, New Zealand, 4Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 5Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand

    Background/Purpose:  Hyperuricaemia and secondary gout are well-recognised complications of diuretic use.  Variants in ABCG2 and SLC2A9 have been identified as the two major genetic risk…
  • Abstract Number: 222 • 2015 ACR/ARHP Annual Meeting

    Serum Delta Neutrophil Index Measurement for Differentiating Acute Gouty Arthritis and Cellulitis in Normouricemic Patients

    Jung Yoon Pyo1, Jason Jungsik Song2, Yong-Beom Park1, Soo-Kon Lee1 and Sang-Won Lee1, 1Yonsei University College of Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

    Background/Purpose: Diagnosis of a patient who comes with acute foot pain is often challenging, because both acute gouty arthritis and cellulitis share common clinical manifestations…
  • Abstract Number: 223 • 2015 ACR/ARHP Annual Meeting

    Increased Platelet Reactivity in Gout: A Potential Mechanism for Adverse Cardiovascular Events

    Richard Conway1, Claire-Louise Murphy2, Anne Madigan2, Patricia Kavanagh2, Liz Geraghty2, Laura Helbert2, Kelly Stephens3, John J. Carey4, Eimear Dunne5, Dermot Kenny5 and Geraldine M. McCarthy6, 1Rheumatology, Mater Misericordiae University Hospital, Dublin 2, Ireland, 2Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, 3Mater Misericordiae University Hospital, Clinical Research Center, Dublin, Ireland, 4Rheumatology, Galway University Hospitals, Galway, Ireland, 5Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, 6University College Dublin, Dublin, Ireland

    Background/Purpose: Patients with inflammatory arthritis, including gout, have an increased risk of cardiovascular events and mortality. Increased platelet reactivity is a risk marker for cardiovascular…
  • Abstract Number: 224 • 2015 ACR/ARHP Annual Meeting

    Silent Monosodium Urate Crystals Deposits in Asymptomatic Hyperuricemia Lead to a Higher Need for Coronary Revascularization

    Mariano Andrés1, María Amparo Quintanilla2, Francisca Sivera3, José Sánchez-Payá4, Juan M Ruiz-Nodar5, Eliseo Pascual1,6 and Paloma Vela1,6, 1Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, 2Sección de Cardiología, Hospital General Universitario de Elda, Alicante, Spain, 3Reumatología, Hospital General Universitario de Elda, Alicante, Spain, 4Servicio de Medicina Preventiva, Hospital General Universitario de Alicante, Alicante, Spain, 5Servicio de Cardiología, Hospital General Universitario de Alicante, Alicante, Spain, 6Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain

    Background/Purpose: Increased cardiovascular (CV) risk in gout relates to crystal-driven inflammation. In a preliminary, cross-sectional study we found that silent deposits of monosodium urate (MSU)…
  • Abstract Number: 225 • 2015 ACR/ARHP Annual Meeting

    Gout Patients Present Carotid Plaques at Presentation in Spite of Low-Risk Cardiovascular Score

    Mariano Andrés1, Francisca Sivera2, José Antonio Bernal1, Neus Quilis1, Loreto Carmona3, Paloma Vela1,4 and Eliseo Pascual1,4, 1Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, 2Reumatología, Hospital General Universitario de Elda, Alicante, Spain, 3Instituto de Salud Musculoesquelética, Madrid, Spain, 4Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain

    Gout patients present carotid plaques at presentation in spite of low-risk cardiovascular score.Background/Purpose: Gout is associated with an increased cardiovascular (CV) risk related to high…
  • Abstract Number: 226 • 2015 ACR/ARHP Annual Meeting

    Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both

    Daisy Bang1, Jinfeng Xu2, Robert T. Keenan3, Virginia Pike1, Aaron Lehmann1, Craig T. Tenner4, Daria Crittenden1, Michael H. Pillinger1 and Svetlana Krasnokutsky1, 1Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, 2Biostatistics, New York University School of Medicine, New York, NY, 3Rheumatology, Duke University, Durham, NC, 4Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Osteoarthritis (OA) and gout are each associated with increased cardiovascular disease (CVD), but their relative impacts on CV risk are not known. We compared…
  • Abstract Number: 227 • 2015 ACR/ARHP Annual Meeting

    Impact of Gout on the Risk of Atrial Fibrillation

    Chang-Fu Kuo1, Matthew J. Grainge2, Weiya Zhang3 and Michael Doherty4, 1Division of Rheumatoplogy, Allergy and Immunology, Chang Gung Memorial Hospital, Tayuan, Taiwan, 2Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom, 3Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, 4Academic Rheumatology, City Hospital, Nottingham, United Kingdom

    Background/Purpose: To examine the risk of atrial fibrillation (AF) at the time of first diagnosis of gout compared to matched controls and to follow incident…
  • Abstract Number: 228 • 2015 ACR/ARHP Annual Meeting

    Gout and Risk of Non-Vertebral Osteoporotic Fracture

    Seoyoung C. Kim1, Julie M. Paik2, Jun Liu3, Gary C. Curhan2 and Daniel H. Solomon4, 1Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Renal Division, Brigham and Women's Hospital, Boston, MA, 3Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Prior studies suggest an association between osteoporosis, systemic inflammation and pro-inflammatory cytokines such as IL-1 and IL-6. Gout is a common inflammatory arthritis characterized…
  • Abstract Number: 229 • 2015 ACR/ARHP Annual Meeting

    Uric Acid and Incident Dementia over 10 Years

    Pascal Richette1, Aicha Soumare2, Stéphanie Debette2, Thomas Bardin3,4 and Christophe Tzourio2, 1Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, 2INSERM Research Center for Epidemiology and Biostatistics (U897) Team Neuroepidemiology, Bordeaux, France, 3Service de Rhumatologie, Hôpital Lariboisière, Paris, France, 4Rhumatology Departement, Hôpital Lariboisière, Paris, France

    Background/Purpose: In patients with gout, maintaining the serum uric acid (SUA) levels too low with ULT is a matter of concern because UA is thought…
  • Abstract Number: 230 • 2015 ACR/ARHP Annual Meeting

    Serum Uric Acid As Short Term Mortality Predictor in the Acute Care Setting

    Yuval Schwartz1, Gideon Nesher2,3 and Gabriel S Breuer3,4, 1Medicine, Shaare Zedek Medical Center, Jerusalem, Israel, 2Internal Medicine, Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, 3Hebrew University School of Medicine, Jerusalem, Israel, 4Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel

    Background/Purpose: Many studies have showed that the serum uric acid (SUA) is an independent predictor of adverse cardiovascular events and all-cause mortality, but some studies…
  • Abstract Number: 231 • 2015 ACR/ARHP Annual Meeting

    Uric Acid Levels Predict Mortality in Women

    Jenni E Kauppi1, Tuomo Nieminen2,3, Mika Kähönen4,5, Anne Kerola6, Antti Jula7, Jaana Leiviskä8 and Markku J. Kauppi9,10, 1School of medicine, University of Tampere, Tampere, Finland, 2Department of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland, 3Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, 4Department of Clinical physiology, School of Medicine, University of Tampere, Tampere, Finland, 5Department of Clinical Physiology, Medical Imaging Centre, Pirkanmaa Hospital District, Tampere, Finland, 6Faculty of Medicine, University of Helsinki, Helsinki, Finland, 7Department of Health, National Institute for Health and Welfare, Turku, Finland, 8Department of Health, National Institute for Health and Welfare, Helsinki, Finland, 9School of Medicine, University of Tampere, Tampere, Finland, 10Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland

    Background/Purpose: Hyperuricemia induces chronic inflammation and is associated with many diseases such as metabolic syndrome, high blood pressure, chronic kidney disease and cardiovascular diseases. The…
  • Abstract Number: 232 • 2015 ACR/ARHP Annual Meeting

    Hyperuricemia, Urate Lowering Therapy and Kidney Function: A Systemic Review and Meta-Analysis

    Gaurav Sharma1, Abhishek Dubey1 and Jasvinder A. Singh2, 1Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India, 2University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: To determine whether hyperuricemia is associated with deterioration of kidney function and to examine whether urate-lowering therapies (ULTs) can improve or maintain kidney function.…
  • Abstract Number: 233 • 2015 ACR/ARHP Annual Meeting

    Gout Does Not Decrease the Risk of Parkinson’s Disease: A Systematic Review and Meta-Analysis

    Patompong Ungprasert1, Charat Thongprayoon2 and Narat Srivali3, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Internal medicine, Bassett medical center, Cooperstown, NY, 3Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN

    Gout Does Not Decrease the Risk of Parkinson's Disease: A Systematic Review and Meta-analysisBackground/Purpose: Uric acid is a potent anti-oxidant and hyperuricemia is well-linked to…
  • « Previous Page
  • 1
  • …
  • 1884
  • 1885
  • 1886
  • 1887
  • 1888
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology